Work

First do no harm

Year: 2022

Type: article

Abstract: For prevention of thrombotic events in patients hospitalized because of COVID‐19, low molecular weight heparin (LMWH) and unfractionated heparin are the rational anticoagulants of choice, given that the overall majority of thromboses are of venous origin.1‐3 In view of the high incidence of venous thromboembolism in ward and in intensive care unit (ICU) patients, a plethora of 75 studies have been registered since the start of the COVID pandemic.4 The majority of these compared therapeutic doses, and to a lesser extent, intermediate doses, versus a standard prophylactic dosis of LMWH in two sets of hospitalized COVID‐19 patients (i.e., ward patients who were named moderately or not critically ill and ICU patients).

Source: Research and Practice in Thrombosis and Haemostasis

DOI: 10.1002/rth2.12694

Authors: Menno V. Huisman, Frederikus A. Klok

Institution: Leiden University Medical Center

Language: English

Topic: Venous Thromboembolism Diagnosis and Management

Subfield: Internal Medicine

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: gold

Estimated APC paid: $2,000